Objective: The purpose of this study was to investigate the clinicopathological characteristics and treatment outcomes of patients with adrenocortical carcinoma (AC). Methods: Twenty-four patients (10 females and 14 males) diagnosed with AC between 1998 and 2009 were evaluated. Clinical features and outcomes were reviewed. Results: Median age was 46.5 years. One (4%) patient was classified as stage I, 10 (42%) were classified as stage II, 8 (33%) were classified as stage III and 5 (21%) were classified as stage IV. Tumor sizes ranged from 3 to 22 cm with a mean diameter of 11 cm. Five patients were locally inoperable at initial diagnosis. In addition to surgery, 2 of 19 patients were treated with an adjuvant cisplatin plus etoposide regimen. Sixteen patients were treated with chemotherapy after recurrence. Median survival time was 18 months. The 1- and 5-year overall survival estimates were 73 and 48%, respectively. Mean survival times for male and female patients were 58 and 12 months, respectively (p = 0.046). Early T stage (p = 0.04), lymph node negativity (p < 0.001), the absence of distant metastases (p < 0.001) and early stage (p < 0.001) were correlated with overall survival. Conclusion: AC is a rare disease with a poor prognosis. There are correlations between gender, stage and survival.

Keywords:
Adrenocortical carcinoma, Clinicopathological characteristics, Survival rates
1.
Vaughan ED Jr: Diseases of the adrenal gland. Med Clin North Am 2004;88:443-466.
2.
Roman S: Adrenocortical carcinoma. Curr Opin Oncol 2006;18:36-42.
3.
Icard P, Goudet P, Charpenay C, Andreassian B, Carnaille B, Chapuis Y, Cougard P, Henry JF, Proye C: Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons Study Group. World J Surg 2001;25:891-897.
4.
Bilimoria KY, Shen WT, Elaraj D, Bentrem DJ, Winchester DJ, Kebebew E, Sturgeon C: Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer 2008;113:3130-3136.
5.
Nishida S, Itoh N, Sasao T, Masumori N, Taguchi K, Tsukamoto T: Adrenocortical carcinoma: retrospective study of 14 patients experienced at a single institution over 34 years. Int J Urol 2007;14:581-584.
6.
Gomez-Rivera F, Medina-Franco H, Arch-Ferrer JE, Heslin MJ: Adrenocortical carcinoma: a single institution experience. Am Surg 2005;71:90-94.
7.
Tauchmanova L, Colao A, Marzano LA, Sparano L, Camera L, Rossi A, Palmieri G, Marzano E, Salvatore M, Pettinato G, Lombardi G, Rossi R: Adrenocortical carcinomas: twelve-year prospective experience. World J Surg 2004;28:896-903.
8.
Vassilopoulou-Sellin R, Schultz PN: Adrenocortical carcinoma. Clinical outcome at the end of the 20th century. Cancer 2001;92:1113-1121.
9.
Tucci S Jr, Martins AC, Suaid HJ, Cologna AJ, Reis RB: The impact of tumor stage on prognosis in children with adrenocortical carcinoma. J Urol 2005;174:2338-2342.
10.
Schulick RD, Brennan MF: Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol 1999;6:719-726.
11.
Dong D, Li H, Yan W, Ji Z, Mao Q: Surgical management and clinical prognosis of adrenocortical carcinoma. Urol Int 2012;88:400-404.
12.
Gomha AM, Osman Y, El-Mekresh M, Abou El-Ghar M, Eraky I: Diagnosis and treatment of adrenal tumors: a single-center experience with 238 cases. Urol Int 2009;83:433-437.
13.
Osman Y, El-Mekresh M, Gomha AM, Mohsen T, Taha N, Hussein N, Eraky I: Percutaneous adrenal biopsy for indeterminate adrenal lesion: complications and diagnostic accuracy. Urol Int 2010;84:315-318.
14.
Brix D, Allolio B, Fenske W, Agha A, Dralle H, Jurowich C, Langer P, Mussack T, Nies C, Riedmiller H, Spahn M, Weismann D, Hahner S, Fassnacht M: Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients. Eur Urol 2010;58:609-615.
15.
Gaujoux S, Brennan MF: Recommendation for standardized surgical management of primary adrenocortical carcinoma. Surgery 2012;152:123-132.
16.
Porpiglia F, Miller BS, Manfredi M, Fiori C, Doherty GM: A debate on laparoscopic versus open adrenalectomy for adrenocortical carcinoma. Horm Cancer 2011;2:372-377.
17.
Bellantone R, Ferrante A, Boscherini M, Lombardi CP, Crucitti P, Crucitti F, Favia G, Borrelli D, Boffi L, Capussotti L, Carbone G, Casaccia M, Cavallaro A, Del Gaudio A, Dettori G, Di Giovanni V, Mazziotti A, Marrano D, Masenti E, Miccoli P, Mosca F, Mussa A, Petronio R, Piat G, Marazano L, et al: Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian national registry for adrenal cortical carcinoma. Surgery 1997;122:1212-1218.
18.
Datrice NM, Langan RC, Ripley RT, Kemp CD, Steinberg SM, Wood BJ, Libutti SK, Fojo T, Schrump DS, Avital I: Operative management for recurrent and metastatic adrenocortical carcinoma. J Surg Oncol 2012;105:709-713.
19.
Veytsman I, Nieman L, Fojo T: Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. J Clin Oncol 2009;27:4619-4629.
20.
Didolkar MS, Bescher RA, Elias EG, Moore RH: Natural history of adrenal cortical carcinoma: a clinicopathologic study of 42 patients. Cancer 1981;47:2153-2161.
21.
Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, Rossetto R, Buci L, Sperone P, Grossrubatscher E, Reimondo G, Bollito E, Papotti M, Saeger W, Hahner S, Koschker AC, Arvat E, Ambrosi B, Loli P, Lombardi G, Mannelli M, Bruzzi P, Mantero F, Allolio B, Dogliotti L, Berruti A: Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 2007;356:2372-2380.
22.
Icard P, Chapuis Y, Andreassian B, Bernard A, Proye C: Adrenocortical carcinoma in surgically treated patients: a retrospective study on 156 cases by the French Association of Endocrine Surgery. Surgery 1992;112:972-979.
23.
Wooten MD, King DK: Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer 1993;72:3145-3155.
24.
Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, Welin S, Schade-Brittinger C, Lacroix A, Jarzab B, Sorbye H, Torpy DJ, Stepan V, Schteingart DE, Arlt W, Kroiss M, Leboulleux S, Sperone P, Sundin A, Hermsen I, Hahner S, Willenberg HS, Tabarin A, Quinkler M, de la Fouchardiere C, Schlumberger M, Mantero F, Weismann D, Beuschlein F, Gelderblom H, Wilmink H, Sender M, Edgerly M, Kenn W, Fojo T, Muller HH, Skogseid B: Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 2012;366:2189-2197.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.